ArticleClinical rheumatology2026
The role of cannabis-based medicinal products (CBMPs) in managing osteoarthritis symptoms: a scoping review of current evidence and future directions.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis review critically evaluates the therapeutic role of cannabis and its derivatives in managing osteoarthritic pain, with a focus on clinical evidence and efficacy of various pharmacological dose and forms.
methodsA literature search was conducted using Medline, EMBASE, CINAHL and COCHRANE databases with the key terms "cannabis", "cannabidiol", "CBD", "osteoarthritis" and "human". Inclusion criteria were limited to studies published in English with full-text access from year 2020 onwards; animal-based laboratory research, narrative surveys, and questionnaire-based studies were excluded.
resultsOut of 517 search results, 19 were included in this review. Initial clinical studies using different CBD formulations and dosages suggest potential benefits for relieving OA symptoms, with topical CBD showing the most encouraging results and an acceptable safety profile. Nonetheless, the overall strength of the evidence is constrained by considerable variability in CBD dosing and product types, as well as the absence of robust comparisons with standard analgesic treatments, making it challenging to determine the true therapeutic value of CBMPs for OA symptom management.
conclusionAlthough cannabinoids provide a strong biological basis as a potentially useful adjunct for managing osteoarthritis-related pain, the current body of evidence does not yet justify their routine clinical use. Challenges such as variability in product quality, absence of consistent prescribing guidelines and regulatory barriers further hinder their integration into practice. Robust, well-designed clinical trials with standardised dosing and formulation protocols are needed to determine the most effective and safe therapeutic approach.
Indexed as
Identifiers
41870683What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.